← Back to Search

D2S Intervention for HIV (D2S Trial)

N/A

Waitlist Available

Led By Denis Nash, PhD

Research Sponsored by City University of New York

Eligibility Criteria Checklist

Specific guidelines that determine who can or cannot participate in a clinical trial

Must have

Timeline

Screening 3 weeks

Treatment Varies

Follow Up 12 months

Awards & highlights

D2S Trial Summary

This trial will help researchers understand how to better help low-income people with HIV achieve viral suppression, which is key to reducing HIV health disparities and scaling up evidence-based interventions.

Who is the study for?

This trial is for low-income individuals in New York City with HIV who are already receiving care but have not achieved viral suppression. They must have had at least one viral load test showing unsuppressed levels and be enrolled in eligible Ryan White HIV/AIDS Program services.Check my eligibility

What is being tested?

The study tests a 'data-to-suppression' (D2S) strategy aimed at improving viral suppression among patients using behavioral health and housing support programs within the Ryan White HIV/AIDS Program, by providing targeted interventions based on surveillance data.See study design

What are the potential side effects?

Since this intervention involves data management and personalized support rather than medication, traditional side effects associated with drugs are not applicable. However, there may be privacy concerns or stress related to increased monitoring.

D2S Trial Timeline

Screening ~ 3 weeks3 visits

Treatment ~ Varies

Follow Up ~ 12 months

Screening ~ 3 weeks

Treatment ~ Varies

Follow Up ~12 months

This trial's timeline: 3 weeks for screening, Varies for treatment, and 12 months for reporting.

Treatment Details

Study Objectives

Outcome measures can provide a clearer picture of what you can expect from a treatment.

Primary outcome measures

Timely viral suppression

Secondary outcome measures

Time to viral suppression

D2S Trial Design

2Treatment groups

Experimental Treatment

Active Control

Group I: Early ImplementationExperimental Treatment1 Intervention

This arm will receive D2S intervention components during Period 1 (Early Implementation) as well as throughout Period 2 of the stepped-wedge trial.

Group II: Delayed ImplementationActive Control1 Intervention

This arm will receive no D2S intervention components during Period 1 (Early Implementation), but will then receive all D2S intervention components in Period 2, starting 12 months later.

Do I qualify?Apply below to find out

Find a Location

Who is running the clinical trial?

New York City Department of Health and Mental HygieneOTHER_GOV

18 Previous Clinical Trials

16,914 Total Patients Enrolled

National Institute of Mental Health (NIMH)NIH

2,789 Previous Clinical Trials

2,688,811 Total Patients Enrolled

City University of New YorkLead Sponsor

17 Previous Clinical Trials

4,034 Total Patients Enrolled

Media Library

Data to Suppression (D2S) Clinical Trial Eligibility Overview. Trial Name: NCT05140421 — N/A

HIV (Human Immunodeficiency Virus) Research Study Groups: Early Implementation, Delayed Implementation

HIV (Human Immunodeficiency Virus) Clinical Trial 2023: Data to Suppression (D2S) Highlights & Side Effects. Trial Name: NCT05140421 — N/A

Data to Suppression (D2S) 2023 Treatment Timeline for Medical Study. Trial Name: NCT05140421 — N/A

Frequently Asked Questions

These questions and answers are submitted by anonymous patients, and have not been verified by our internal team.

Are researchers still enrolling participants for this research endeavor?

"Regrettably, this medical trial is no longer accepting patients. Its original posting date was December 15th 2021 and it last updated its status on March 18th 2022. Nevertheless, there are 562 other trials currently recruiting participants at this moment in time."

Answered by AI